JPMorgan Downgrades Karuna Therapeutics Inc. to Neutral

KRTXDelisted Stock  USD 203.11  1.46  0.71%   
Slightly above 62% of Karuna Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Karuna Therapeutics suggests that many traders are alarmed regarding Karuna Therapeutics' prospects. Karuna Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Karuna Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
JPMorgan analyst Jessica Fye downgraded Karuna Therapeutics Inc. from Overweight to Neutral with a price target of 330.00 . For an analyst ratings summary and...

Read at streetinsider.com
Street Insider News
  

Karuna Therapeutics Fundamental Analysis

We analyze Karuna Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karuna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karuna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

Karuna Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Karuna Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karuna Therapeutics stock to make a market-neutral strategy. Peer analysis of Karuna Therapeutics could also be used in its relative valuation, which is a method of valuing Karuna Therapeutics by comparing valuation metrics with similar companies.

Peers

Karuna Therapeutics Related Equities

TERNTerns Pharmaceuticals   3.41   
0%
55.0%
CYTKCytokinetics   1.74   
0%
28.0%
EWTXEdgewise Therapeutics   1.33   
0%
21.0%
BPMCBlueprint Medicines   1.12   
18.0%
0%
DAWNDay One   1.81   
29.0%
0%
MREOMereo BioPharma   2.20   
36.0%
0%
APLSApellis Pharmaceuticals   2.23   
36.0%
0%
ABOSAcumen Pharmaceuticals   2.98   
48.0%
0%
AMLXAmylyx Pharmaceuticals   3.60   
59.0%
0%
DYNDyne Therapeutics   3.79   
62.0%
0%
XFORX4 Pharmaceuticals   5.13   
84.0%
0%
INZYInozyme Pharma   6.09   
100.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Other Consideration for investing in Karuna Stock

If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bonds Directory
Find actively traded corporate debentures issued by US companies
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.